These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 29784048)

  • 1. A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema.
    He Y; Ren XJ; Hu BJ; Lam WC; Li XR
    BMC Ophthalmol; 2018 May; 18(1):121. PubMed ID: 29784048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal steroids for macular edema in diabetes.
    Rittiphairoj T; Mir TA; Li T; Virgili G
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005656. PubMed ID: 33206392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.
    Mehta H; Hennings C; Gillies MC; Nguyen V; Campain A; Fraser-Bell S
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011599. PubMed ID: 29669176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of dexamethasone intravitreal implant with intravitreal anti-VEGF injections for the treatment of macular edema secondary to branch retinal vein occlusion: A meta-analysis.
    Ji K; Zhang Q; Tian M; Xing Y
    Medicine (Baltimore); 2019 May; 98(22):e15798. PubMed ID: 31145307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion-related macular edema: A systematic review and meta-analysis of randomized controlled trials.
    Hu Q; Li H; Xu W; Du Y; Ma C; He J
    Indian J Ophthalmol; 2019 Nov; 67(11):1800-1809. PubMed ID: 31638037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema.
    Busch C; Zur D; Fraser-Bell S; Laíns I; Santos AR; Lupidi M; Cagini C; Gabrielle PH; Couturier A; Mané-Tauty V; Giancipoli E; Ricci GD; Cebeci Z; Rodríguez-Valdés PJ; Chaikitmongkol V; Amphornphruet A; Hindi I; Agrawal K; Chhablani J; Loewenstein A; Iglicki M; Rehak M;
    Acta Diabetol; 2018 Aug; 55(8):789-796. PubMed ID: 29730822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study.
    Gillies MC; Lim LL; Campain A; Quin GJ; Salem W; Li J; Goodwin S; Aroney C; McAllister IL; Fraser-Bell S
    Ophthalmology; 2014 Dec; 121(12):2473-81. PubMed ID: 25155371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study.
    Augustin AJ; Kuppermann BD; Lanzetta P; Loewenstein A; Li XY; Cui H; Hashad Y; Whitcup SM;
    BMC Ophthalmol; 2015 Oct; 15():150. PubMed ID: 26519345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results.
    Busch C; Fraser-Bell S; Iglicki M; Lupidi M; Couturier A; Chaikitmongkol V; Giancipoli E; Rodríguez-Valdés PJ; Gabrielle PH; Laíns I; Santos AR; Cebeci Z; Amphornphruet A; Degenhardt V; Unterlauft JD; Cagini C; Mané-Tauty V; D'Amico Ricci G; Hindi I; Agrawal K; Chhablani J; Loewenstein A; Zur D; Rehak M;
    Acta Diabetol; 2019 Dec; 56(12):1341-1350. PubMed ID: 31541334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
    Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing the efficacy of dexamethasone implant and anti-VEGF for the treatment of macular edema: A systematic review and meta-analysis.
    Tang HX; Li JJ; Yuan Y; Ling Y; Mei Z; Zou H
    PLoS One; 2024; 19(7):e0305573. PubMed ID: 38985778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal bevacizumab and dexamethasone implant for treatment of chronic diabetic macular edema.
    Güler E; Totan Y; Betül Güragaç F
    Cutan Ocul Toxicol; 2017 Jun; 36(2):180-184. PubMed ID: 28366074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-VEGF versus dexamethasone implant (Ozurdex) for the management of Centre involved Diabetic Macular Edema (CiDME): a randomized study.
    Sharma A; Bellala K; Dongre P; Reddy P
    Int Ophthalmol; 2020 Jan; 40(1):67-72. PubMed ID: 31377905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of intravitreal dexamethasone implant and anti-VEGF drugs in the treatment of retinal vein occlusion-induced oedema: a meta-analysis and systematic review.
    Ming S; Xie K; Yang M; He H; Li Y; Lei B
    BMJ Open; 2020 Jun; 10(6):e032128. PubMed ID: 32595145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal dexamethasone implants versus intravitreal anti-VEGF treatment in treating patients with retinal vein occlusion: a meta-analysis.
    Gao L; Zhou L; Tian C; Li N; Shao W; Peng X; Shi Q
    BMC Ophthalmol; 2019 Jan; 19(1):8. PubMed ID: 30621640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial.
    Maturi RK; Glassman AR; Liu D; Beck RW; Bhavsar AR; Bressler NM; Jampol LM; Melia M; Punjabi OS; Salehi-Had H; Sun JK;
    JAMA Ophthalmol; 2018 Jan; 136(1):29-38. PubMed ID: 29127949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dexamethasone Intravitreal Implant for Chronic Diabetic Macular Edema Resistant to Intravitreal Bevacizumab Treatment.
    Totan Y; Güler E; Gürağaç FB
    Curr Eye Res; 2016; 41(1):107-13. PubMed ID: 25610946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COMPARISON OF INTRAVITREAL DEXAMETHASONE IMPLANT AND AFLIBERCEPT IN PATIENTS WITH TREATMENT-NAIVE DIABETIC MACULAR EDEMA WITH SEROUS RETINAL DETACHMENT.
    Ozsaygili C; Duru N
    Retina; 2020 Jun; 40(6):1044-1052. PubMed ID: 30950970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 12-MONTH, SINGLE-MASKED, RANDOMIZED CONTROLLED STUDY OF EYES WITH PERSISTENT DIABETIC MACULAR EDEMA AFTER MULTIPLE ANTI-VEGF INJECTIONS TO ASSESS THE EFFICACY OF THE DEXAMETHASONE-DELAYED DELIVERY SYSTEM AS AN ADJUNCT TO BEVACIZUMAB COMPARED WITH CONTINUED BEVACIZUMAB MONOTHERAPY.
    Maturi RK; Bleau L; Saunders J; Mubasher M; Stewart MW
    Retina; 2015 Aug; 35(8):1604-14. PubMed ID: 25829346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal dexamethasone implant versus anti-VEGF injection for treatment-naïve patients with retinal vein occlusion and macular edema: a 12-month follow-up study.
    Chiquet C; Dupuy C; Bron AM; Aptel F; Straub M; Isaico R; Romanet JP; Creuzot-Garcher C
    Graefes Arch Clin Exp Ophthalmol; 2015 Dec; 253(12):2095-102. PubMed ID: 25673251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.